| Balance sheet (USD) | Q4 2026 ended Jun 30, 2026 | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 832.0K | 443.7K | 561.2K | 602.7K | 12.1K | 50.8K | 14.6K | 9.3K |
| Total current assets | 8.54M | 8.22M | 7.71M | 8.76M | 8.35M | 9.74M | 18.0K | 21.5K |
| Property, plant and equipment | 3.9K | 4.2K | 4.4K | 2.4K | ||||
| Total assets | 12.78M | 14.33M | 15.11M | 17.98M | 19.63M | 22.53M | 78.5K | 63.6K |
| Accounts payable | 1.13M | 973.7K | 957.5K | 1.07M | 1.25M | 1.12M | 1.22M | 1.24M |
| Total current liabilities | 3.35M | 3.48M | 3.62M | 3.57M | 5.58M | 4.34M | 4.15M | 4.10M |
| Long-term debt | 55.0K | 55.0K | 107.0K | 537.9K | 438.6K | 409.8K | 381.8K | |
| Total liabilities | 3.38M | 3.51M | 3.66M | 3.61M | 5.73M | 4.44M | 4.24M | 4.17M |
| Retained earnings | -144.48M | -140.84M | -134.48M | -130.46M | -125.62M | -121.55M | -67.48M | -67.05M |
| Shareholders' equity | 9.40M | 9.83M | 10.45M | 14.36M | 13.91M | 18.09M | -4.16M | -4.11M |
| Total debt | 55.0K | 55.0K | 107.0K | 537.9K | 438.6K | 409.8K | 381.8K | |
| Net debt | -388.7K | -506.2K | -495.8K | 525.8K | 387.8K | 395.2K | 372.5K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.